针对血管形的有针对性的治疗方法:当前的技术状况
Emmanuel Seront1, Cedric Hermans2, Laurence M Boon3
1Center for Vascular Anomalies (a VASCERN VASCA European Reference Centre), Cliniques universitaires St Luc, University of Louvain, Brussels, Belgium. Electronic address: https://twitter.com/emmanuelseront.
Journal of thrombosis and haemostasis : JTH
|August 3, 2024
概括
向分子抑制剂,类似于用于癌症治疗的向分子抑制剂,显示出治疗血管形的前景. 重新利用这些药物为管理这些复杂的血管异常提供了新的希望.
科学领域:
- 血管生物学和医学
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 血管形是血管发育的先天性异常.
- 目前的治疗方法,如硬化疗法和手术,在复杂的病例中取得了有限的成功.
- 许多形与癌症有着共同的遗传基础,涉及关键信号通路.
研究的目的:
- 审查针对性分子抑制剂治疗血管形的潜力.
- 探索这些疾病的抗癌药物的重新用途.
- 讨论缓慢流,快速流,产前和凝血相关形的应用.
主要方法:
- 关于针对血管形的向治疗的最新进展的文献综述.
- 对血管形和癌症常见的遗传途径的分析.
- 对重新使用的抗癌药物进行有效性和安全性的评估.
主要成果:
- 血管形通常涉及PI3K-AKT-mTOR,RAS-MAPK-ERK和GPCR通路的突变,类似于癌症.
- 针对这些途径的向抑制剂正在成为有效的治疗方法.
- 这些药物显示出各种类型的血管形的潜力,包括复杂和产前病例.
结论:
- 向分子疗法代表了血管形治疗的有希望的新前沿.
- 重用抗癌药物提供了一个可行的策略来管理这些条件.
- 需要进一步的研究来优化治疗方案,并扩大临床应用.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Mechanism of Angiogenesis
5.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.4K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


